Researchers have discovered 23 proteins in breast milk that could indicate breast cancer, paving the way for a potential blood test. The study's findings, if confirmed, may enable earlier diagnosis and improve survival rates.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
Researchers at the University of Houston have identified a new biomarker, NPY1R, that predicts therapy outcome and has potential as a drug target in estrogen receptor-positive breast cancer. The study found that NPY1R expression is associated with favorable outcomes in Luminal A subtype breast cancer, but declines in resistant cases.
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
Researchers have opened a novel study for a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. The phase I trial will determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer.
A new study found that surgery benefits men with Stage IV breast cancer, particularly those responsive to systemic therapy. Trimodal therapy, including surgery and radiation, shows improved 5-year overall survival rates compared to systemic therapy alone.
Women with dense breast tissue are at increased risk of developing breast cancer, which can be masked by mammograms. Mayo Clinic expert Suneela Vegunta recommends supplemental screening to diagnose additional cancers; however, consensus-based guidelines and randomized controlled studies are needed.
A new study from the University of Eastern Finland and Kuopio University Hospital found that liquid biopsy can accurately identify patients with poor breast cancer prognosis. High integrity of circulating DNA is associated with a poor prognosis, enabling earlier and more accurate detection of breast cancer. The study's findings have si...
Scientists have developed a new mouse model that enables the growth and metastatic spread of human breast tumors in mice. This breakthrough could lead to more effective treatments for estrogen receptor-positive breast cancer, which is responsible for most breast cancer deaths.
For women with extremely dense breasts, MRI screenings have been found to be more effective than mammography in detecting breast cancer. The additional costs of MRI screenings are more than compensated by their improved effectiveness in preventing death from breast cancer.
A new study finds that left-sided breast cancer radiation therapy increases the risk of coronary artery disease in younger survivors, with a significant increase in risk seen at 10.5% for those who received left-sided radiation therapy compared to 5.8% for right-sided.
A new treatment approach investigated by researchers at the Garvan Institute of Medical Research may help stop breast cancer cells from spreading. By targeting a signalling molecule called Rac1, the study found that breast cancer cells became more vulnerable to physical stresses in the bloodstream and less likely to survive the journey.
A new study uses deep learning to predict breast cancer risk from mammograms, outperforming clinical risk factors in distinguishing between women who will develop cancer and those who won't. The findings have significant implications for breast cancer management, suggesting a potential role for AI as a second reader for radiologists.
A new study found that breast cancer screening rates dropped significantly among women aged 50-74 at community health centers serving lower-income populations. The decline would have resulted in 47,517 fewer mammograms and 242 missed breast cancer diagnoses if trends had continued.
Researchers developed prediction models to distinguish true-positives from false-positives in MRI screenings, reducing recalls and biopsies without missing cancers. The models, based on clinical characteristics and imaging findings, could have prevented 45.5% of false-positive recalls and 21.3% of benign biopsies.
A significant association was found between statin use and improved outcomes in women with stage I-III triple-negative breast cancer. Statin use was associated with a 58% relative improvement in breast cancer-specific survival and a 30% relative improvement in overall survival.
A new study by Mayo Clinic researchers suggests that most women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing. The study found mutations in actionable breast cancer risk genes in 3.2% of women with breast cancer, highlighting the need for broader testing regardless of age or family history.
The COVID-19 pandemic has been linked to a potential increase in breast cancer mortality, with estimated excess deaths reaching 2,487 by 2030. Researchers used simulation models to predict the impact of screening, diagnosis, and treatment disruptions on breast cancer mortality.
Researchers found that diet can alter the breast microbiome to affect breast cancer risk. The study, published in Cancer Research, showed that a high-fat diet led to more aggressive tumors and reduced effectiveness of fish oil supplements.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
Researchers created an RNA atlas detailing the diverse cells in healthy and cancerous breast tissue, revealing changes that occur during cancer development. The study provides a high-resolution view of breast tissue cell types and will be an important resource for breast cancer research.
A new study reveals that higher body mass index (BMI) is associated with worse survival in early breast cancer patients but improved survival in advanced disease. The 'obesity paradox' highlights the need to understand the biological basis of obesity impacts on breast cancer diagnosis and treatment.
Recent studies at VCU Massey Cancer Center discovered a link between prolactin and breast cancer development. The hormone was found to act as a major contributor to breast cancer growth and could inform the creation of targeted drugs to treat multiple forms of the disease.
A comprehensive systematic review of epidemiological research found a link between certain endocrine-disrupting chemicals and increased breast cancer risk. For example, DDT, PCBs, and PFOA were associated with higher breast cancer incidence in some studies, while phytoestrogens like genistein showed potential protective effects.
Researchers found that breast cancer cells trigger uncontrolled inflammation and remodel tissue, making the cancer more aggressive. The study suggests targeting inflammatory pathways could improve treatment outcomes for pregnant women with breast cancer.
A new study by NYU Rory Meyers College of Nursing found that breast cancer survivors with high genomic test scores report higher overall fear and greater perceived consequences compared to those with low scores. Anxiety and emotional response to cancer are the best predictors of fear, explaining 58% of variance in fear of recurrence.
Women with breast cancer who consumed non-diet soda five times or more per week were 85% more likely to die from breast cancer. The study also found a 62% higher likelihood of dying from any causes among these patients compared to those who never drank non-diet soda.
UC researchers found that cooperation between HER2 and MED1 genes promotes breast tumor growth, spread, and treatment resistance. Targeting MED1 alone or in combination with current therapies may be an effective treatment strategy for nearly 90% of breast cancer patients.
A trial in Mumbai found that regular clinical breast examination led to earlier diagnosis and reduced deaths from breast cancer, especially among women aged 50 and older. The study suggests that implementation of population screening by trained health workers is feasible in low and middle income countries.
A mammography screening strategy based on a baseline breast density measure at age 40 is the most effective and cost-effective way to reduce breast cancer mortality. The study suggests that this approach can lead to a significant reduction in breast cancer mortality, but also increases the number of mammograms performed and false posit...
A study of 44,541 women found that taking metformin to treat type 2 diabetes may protect against developing ER-positive breast cancer. However, the risk of triple negative breast cancer was increased by 74% among those treated with metformin. The link between type 2 diabetes and breast cancer varied by breast cancer subtype.
Researchers at NUI Galway have contributed to a significant international study identifying nine specific genes linked to breast cancer risk. The study, published in the New England Journal of Medicine, used DNA samples from 2,000 Irish patients and controls to uncover key genetic associations.
A new multi-institution study provides more accurate estimates of breast cancer risk for US women with inherited mutations in breast cancer predisposition genes. The findings may allow healthcare providers to better assess the risk of breast cancer and provide more appropriate risk management strategies.
Researchers have found that androgen receptor activation by natural androgens or a new drug has potent anti-tumour activity in all estrogen receptor positive breast cancers, even those resistant to current treatments. This study provides new evidence for an alternative treatment strategy.
Researchers found that surgery in addition to treatments like chemotherapy and radiation therapy increased survival for stage four breast cancer patients. Patients with hormone receptor-positive tumors saw a prolonged length of survival when their treatment plan included surgery.
Researchers found that surgery in addition to treatments like chemotherapy and radiation therapy increased the length of survival for stage four breast cancer patients. The study, published in Annals of Surgical Oncology, suggests that knowing a cancer's biological subtype can help determine effective treatment plans.
ReceptorNet, a deep-learning algorithm developed by Salesforce Research, can determine hormone-receptor status from inexpensive tissue images, improving treatment decision-making for breast cancer patients. This technology has the potential to make high-quality therapies more accessible globally.
For older patients with hormone receptor-positive breast cancer, omitting postoperative radiation therapy did not compromise survival or increase risk of distant metastasis. Local recurrence rates were higher in those who didn't receive radiation therapy.
The Oncotarget journal has launched a special collection on breast cancer, featuring newly published scientific papers on prognostic markers, risk factors, therapies, and gene studies. This free-to-read resource aims to promote a better understanding of the latest breast cancer research.
Researchers are exploring unique biomarkers in normal breast tissue of Black women to improve treatment options for aggressive breast cancer. DNA analysis revealed a genetic mutation called duffy, which may contribute to higher breast cancer rates and aggressiveness in Black women.
A new study reveals that women over 65 with breast cancer have a significant risk of developing the disease due to disease-causing mutations in predisposition genes. The researchers found that up to 20% of these women may still be at high risk for breast cancer, even without prior diagnosis.
A recent study published in the American College of Surgeons found that over 80% of young women can successfully breastfeed or bottle-feed after undergoing surgery for benign breast conditions. The research aimed to address concerns among breast surgeons and pediatricians about the impact of surgery on future breastfeeding capability.
A study by Spanish researchers found that women with incident, proliferative benign breast disease are at a nearly four-fold increased risk of developing breast cancer compared to those with no BBD. The study analyzed data from over 629,000 women and recommends personalized screening strategies based on individual risk factors.
Research published in Nature Precision Oncology reveals that honeybee venom and its compound melittin rapidly destroy triple-negative and HER2-enriched breast cancer cells. The venom's potency allows for selective cell death with minimal effects on normal cells.
A study by Hokkaido University scientists found that Interleukin-34 is a prognostic marker and drug target for Triple Negative Breast Cancer. High levels of IL-34 were associated with poor prognosis in TNBC patients.
A Singapore breast surgical unit developed strategies to balance COVID-19 battle with breast cancer care, emphasizing multidisciplinary teamwork and patient stratification. Prompt adaptation to restricted resources and balancing risks are crucial in providing optimal patient care.
A new immunotherapy approach using nanoparticles has shown promising results in extending the survival of mice with triple negative breast cancer. The treatment, which incorporates oxidized tumor cell lysates, triggered a stronger immune response and led to complete remission in two-thirds of treated mice.
A new study led by Queen Mary University of London found that breast screening women aged 40-49 reduces breast cancer mortality with minimal increased overdiagnosis. The study analyzed data from 160,000 women and found a 25% reduction in breast cancer mortality in the first ten years.
A new study reveals significant increases in premenopausal breast cancer rates globally, particularly in higher-income nations like Canada. The study also finds that postmenopausal breast cancer is increasing more rapidly in lower-income countries, often due to adopting Western lifestyles and lack of early screening.
Researchers found that TMEM165 expression levels alter N-linked glycosylation, promoting the invasion and growth of breast cancer cells. This study suggests a novel role for TMEM165 as a driver of tumor invasion and identifies it as a potential biomarker for breast carcinoma.
Researchers at Johns Hopkins University School of Medicine discovered that breast cancer cells can alter the function of NK cells to facilitate their spread. The study suggests preventing this reprogramming might stop breast cancer from metastasizing, a major cause of death in breast cancer patients.
A new study suggests that early initiation of annual breast cancer screening with MRI and mammography may reduce breast cancer mortality by half or more in female childhood cancer survivors previously exposed to chest radiation. The findings highlight the importance of MRI in reducing deaths from breast cancer in this population.
Research by the University of North Carolina at Chapel Hill found significantly higher medical costs for treating metastatic breast cancer in younger women compared to earlier-stage cancer patients or those without cancer. Treatment continues for longer and includes end-of-life care, contributing to high costs.
A recent study found that women diagnosed with ductal carcinoma in situ (DCIS) are at a significantly higher risk of developing invasive breast cancer and dying from breast cancer, even up to 20 years after diagnosis. The risks were more than double those of the general population.
Boosting the activity of tumor proteasomes could improve chemotherapy treatment outcomes and enhance immunotherapy for aggressive triple-negative breast cancer. Researchers analyzed 3,500 breast tumors to make this finding.
Researchers identified two novel biomarkers, PDL1/CD274 copy number alteration and PD-L1 combined positive score, that correlate with improved outcomes in patients with metastatic breast cancer treated with immunotherapy. These biomarkers may help identify patients most likely to benefit from this treatment.
Scientists have identified key mechanisms within cells that disrupt breast cancer development when exposed to environmental chemicals. The study provides a roadmap for regulators to identify potential breast carcinogens and develop safer products.
Researchers found that African American women have a higher risk of breast cancer due to shared genes with white women, including BRCA1, BRCA2, and PALB2. Current breast cancer testing panels can be used for African American women, increasing the chances of early detection and prevention.
A recent study has identified 32 new sites on the human genome where variations in DNA appear to alter the risks of getting specific subtypes of breast cancer. The analysis, covering over 266,000 women, may eventually improve the ability to predict breast cancer risks at a subtype level.